Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Immunology | Hematology
 Disease Category: Non-Hodgkin's Lymphoma
Location: United States, CA

Trial Information

A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients with B-Cell Non-Hodgkin Lymphoma

You have been asked to participate in this research study because you have B-cell non-Hodgkin lymphoma that has relapsed (returned) or progressed (become worse) after standard therapy. The purpose of this study is to find the highest dose of the investigational agent DI-Leu16-IL2 that can be given without causing unmanageable side effects. Studies will also be done to evaluate the effects of DI-Leu16-IL2 on the immune system and what immune reactions it causes. A series of blood tests will be done to see how long the drug stays in the body. Standard imaging scans will be done to see the effect of DI-Leu16-IL2 on the size of lymphomas. Participation on this study involves receiving a 4-week cycle of treatment and 2-3 week follow-up (6-7 weeks total for one cycle). If you are not experiencing unmanageable side effects, you might be eligible for a second cycle of treatment and follow-up for a total of 12-14 weeks of participation.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.